Overview

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

Status:
RECRUITING
Trial end date:
2029-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, or another solid tumor that makes a higher than normal amount of XPO1 or has genetic changes that increase the activity of XP01.
Phase:
PHASE2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Treatments:
selinexor